peritoneal carcinomatosis

Semin Oncol. 2011 Aug;38(4):568-75. 

Management of peritoneal carcinomatosis from colorectal cancer.

Ihemelandu CU, Shen P, Stewart JH, Votanopoulos K, Levine EA.

Source

Surgical Oncology Service, Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

Abstract

The management of peritoneal carcinomatosis from colorectal cancer is evolving. 

The introduction of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients with metastatic colorectal cancer.

Traditionally, patients with limited hepatic or pulmonary metastases were the only candidates for metastasectomy. However, patients with metastasis localized to the peritoneum have been shown to be candidates for metastasectomy with improved clinical outcomes. 

Cytoreductive surgery with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) in this cohort of patients offers the only chance for long-term survival. 

Complete cytoreduction in combination with HIPEC for peritoneal surface disease has been demonstrated to produce survival outcomes similar to liver resection for hepatic metastases.

This review will examine recent evidence pertaining to the evolving surgical oncology paradigm for management of colorectal peritoneal carcinomatosis.